326 related articles for article (PubMed ID: 10632251)
1. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
Yu T; Padula WV; Yieh L; Gong CL
Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
DeVincenzo JP; Ambrose CS; Makari D; Weiner LB
Hum Vaccin Immunother; 2016 Apr; 12(4):971-5. PubMed ID: 26889568
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
Blanken MO; Frederix GW; Nibbelke EE; Koffijberg H; Sanders EAM; Rovers MM; Bont L;
Eur J Pediatr; 2018 Jan; 177(1):133-144. PubMed ID: 29168012
[TBL] [Abstract][Full Text] [Related]
5. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants.
Shefali-Patel D; Paris MA; Watson F; Peacock JL; Campbell M; Greenough A
Eur J Pediatr; 2012 Jul; 171(7):1055-61. PubMed ID: 22302458
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
7. Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update.
Levin JC; Beam AL; Fox KP; Hayden LP
Am J Perinatol; 2024 May; 41(S 01):e133-e141. PubMed ID: 35523410
[TBL] [Abstract][Full Text] [Related]
8. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
Ambrose CS; Chen X; Kumar VR
Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
Morris SK; Dzolganovski B; Beyene J; Sung L
BMC Infect Dis; 2009 Jul; 9():106. PubMed ID: 19575815
[TBL] [Abstract][Full Text] [Related]
10. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
Ginsberg GM; Somekh E; Schlesinger Y
Isr J Health Policy Res; 2018 Dec; 7(1):63. PubMed ID: 30554570
[TBL] [Abstract][Full Text] [Related]
11. Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.
Mauskopf J; Margulis AV; Samuel M; Lohr KN
Pediatr Infect Dis J; 2016 Jul; 35(7):e229-38. PubMed ID: 27093166
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
Paes B; Mitchell I; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2703-11. PubMed ID: 22546928
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.
Resch B; Bramreiter VS; Kurath-Koller S; Freidl T; Urlesberger B
Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1057-1062. PubMed ID: 28078558
[TBL] [Abstract][Full Text] [Related]
14. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
Straňák Z; Saliba E; Kosma P; Posfay-Barbe K; Yunis K; Farstad T; Unnebrink K; van Wyk J; Wegzyn C; Notario G; Kalus S; Campbell FJ
PLoS One; 2016; 11(6):e0157446. PubMed ID: 27310438
[TBL] [Abstract][Full Text] [Related]
15. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.
Paes B; Mitchell I; Li A; Harimoto T; Lanctôt KL
Clin Dev Immunol; 2013; 2013():917068. PubMed ID: 23861694
[TBL] [Abstract][Full Text] [Related]
16. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.
Maksić H; Heljić S; Skokić F; Šumanović-Glamuzina D; Milošević V; Zlatanović A; Gerard N
Bosn J Basic Med Sci; 2018 Aug; 18(3):279-288. PubMed ID: 29750895
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.
Chang SG; Park MS; Yu JE
J Korean Med Sci; 2010 Feb; 25(2):251-6. PubMed ID: 20119579
[TBL] [Abstract][Full Text] [Related]
18. Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study.
Silvestri M; Marando F; Costanzo AM; di Luzio Paparatti U; Rossi GA
Ital J Pediatr; 2016 Apr; 42():40. PubMed ID: 27112952
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab for the prevention of respiratory syncytial virus infection.
Rogovik AL; Carleton B; Solimano A; Goldman RD
Can Fam Physician; 2010 Aug; 56(8):769-72. PubMed ID: 20705882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
